My ePortfolio Register   

Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analyses

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.04.17
Views: 1167

Prof Peter Schmid - Barts Cancer Institute, London, UK

Prof Schmid speaks with ecancer at AACR 2017 about the results from 150 triple negative breast cancer patients treated with atezolizumab. 

He highlights the best response to atezolizumab was among those receiving it as a first line therapy, and that the duration of response can reach up to 21 months. 

Median overall survival in the study remained at ~9 months, though responsive patients survival reached up to 2 years, which Prof Schmid describes as small subgroup.

He goes on to describe his hopes for combination therapies which can deliver the same survival benefits to more patients.

You can watch Prof Schmid present these results to the conference here.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence